Large-scale purification and characterization of malaria vaccine candidate antigen Pvs25H for use in clinical trials

Protein Expression and Purification

Volumn 25, Issue 1, 2002, Pages 87-96

  Miles, Aaron P ^a   Zhang, Yanling ^a   Saul, Allan ^a   Stowers, Anthony W ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMODIUM VIVAX; SACCHAROMYCES; SACCHAROMYCES CEREVISIAE; SACCHAROMYCETALES;

EID: 0036931119     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1006/prep.2001.1613     Document Type: Article

References (14)

1. Mendis, K., Sina, B. J., Marchesini, P., and Carter, R. (2001) The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 64, 97-106.
2. Harinasuta, T., Suntharasamai, P., and Viravan, C. (1965) Chloroquine-resistant falciparum malaria in Thailand. Lancet 2, 657-660.
3. Rieckmann, K. H., Davis, D. R., and Hutton, D. C. (1989) Plasmodium vivax resistance to chloroquine? Lancet 2, 1183-1184.
4. Roberts, D. R., and Andre, R. G. (1994) Insecticide resistance issues in vector-borne disease control. Am. J. Trop. Med. Hyg. 50, 21-34.
5. Good, M. F., Kaslow, D. C., and Miller, L. H. (1998) Pathways and strategies for developing a malaria blood-stage vaccine. Annu. Rev. Immunol. 16, 57-87.
6. Kaslow, D. C. (1997) Transmission-blocking vaccines: Uses and current status of development. Int. J. Parasitol. 27, 183-189.
7. Tsuboi, T., Kaslow, D. C., Gozar, M. M., Tachibana, M., Cao, Y. M., and Torii, M. (1998) Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Mol. Med. 4, 772-782.
8. Hisaeda, H., Stowers, A. W., Tsuboi, T., Collins, W. E., Sattabongkot, J. S., Suwanabun, N., Torii, M., and Kaslow, D. C. (2000) Antibodies to malaria vaccine candidates pvs25 and pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect. Immun. 68, 6618-6623.
9. Stowers, A. W., Zhang, Y., Shimp, R. L., and Kaslow, D. C. (2001) Structural conformers produced during malarial vaccine production in yeast. Yeast 18, 137-150.
10. Keitel, W. A., Kester, K. E., Atmar, R. L., White, A. C., Bond, N. H., Holland, C. A., Krzych, U., Palmer, D. R., Egan, A., Diggs, C., Ballou, W. R., Hall, B. F., and Kaslow, D. (1999) Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine 18, 531-539.
11. Stowers, A. W., Keister, D. B., Muratova, O., and Kaslow, D. C. (2000) A region of plasmodium falciparum antigen pfs25 that is the target of highly potent transmission-blocking antibodies [in process citation]. Infect. Immun. 68, 5530-5538.
12. Kaslow, D. C., and Shiloach, J. (1994) Production, purification and immunogenicity of a malaria transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose. Biotechnology (N.Y.) 12, 494-499.
13. Bause, E., and Legler, G. (1981) The role of the hydroxy amino acid in the triplet sequence Asn-Xaa-Thr(Ser) for the N-glycosylation step during glycoprotein biosynthesis. Biochem. J. 195, 639-644.
14. Miletich, J. P., and Broze, G. J., Jr. (1990) Beta protein C is not glycosylated at asparagine 329: The rate of translation may influence the frequency of usage at asparagine-X-cysteine sites. J. Biol. Chem. 265, 11397-11404.